Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-063634
Filing Date
2025-05-05
Accepted
2025-05-05 16:47:38
Documents
96
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q axsm-20250331.htm   iXBRL 10-Q 2605594
2 EX-10.1 axsm-ex10_1.htm EX-10.1 236955
3 EX-10.2 axsm-ex10_2.htm EX-10.2 61156
4 EX-10.3 axsm-ex10_3.htm EX-10.3 79987
5 EX-10.4 axsm-ex10_4.htm EX-10.4 81342
6 EX-31.1 axsm-ex31_1.htm EX-31.1 16475
7 EX-31.2 axsm-ex31_2.htm EX-31.2 16359
8 EX-32.1 axsm-ex32_1.htm EX-32.1 7818
9 EX-32.2 axsm-ex32_2.htm EX-32.2 7796
  Complete submission text file 0000950170-25-063634.txt   11917493

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT axsm-20250331.xsd EX-101.SCH 1651187
99 EXTRACTED XBRL INSTANCE DOCUMENT axsm-20250331_htm.xml XML 2018607
Mailing Address ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007
Business Address ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007 (212) 332-3241
Axsome Therapeutics, Inc. (Filer) CIK: 0001579428 (see all company filings)

EIN.: 454241907 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37635 | Film No.: 25913707
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)